Explore the Role of the Sphingosine-1-Phosphate Signalling as a Novel Promising Therapeutic Target for the Management of Parkinson's Disease

被引：0
|
作者：
Bisht, Manoj [1 ]
Kadian, Jai Parkash [2 ]
Akhilesh [3 ]
Hooda, Tanuj [4 ]
Jain, Neelam [5 ]
Lather, Amit [4 ]
Aggarwal, Navidha [4 ]
机构：
[1] Devasthali Vidyapeeth Coll Pharm, Rudrapur, Uttarakhand, India
[2] Shobhit Univ, Adarsh Vijendra Inst Pharmaceut Sci, Saharanpur, UP, India
[3] IIT BHU, Dept Pharmaceut Engn & Technol, Varanasi, UP, India
[4] Maharishi Markandeshwar Deemed Univ, MM Coll Pharm, Mullana Ambala 133207, Haryana, India
[5] Bhagat Phool Singh Mahila Vishwavidyalaya, Dept Pharmaceut Educ & Res, Sonepat, Haryana, India
来源：
DRUG RESEARCH | 2024年 / 74卷 / 08期
关键词：
central nervous system; neuroinflammation; neuroprotective; Parkinson's disease; sphingosine 1-phosphate (S1P) signalling; CENTRAL-NERVOUS-SYSTEM; SPHINGOSINE KINASE; NONMOTOR SYMPTOMS; MOUSE MODEL; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; ALPHA-SYNUCLEIN; CERAMIDE; FINGOLIMOD; DIAGNOSIS;
D O I：
10.1055/a-2401-4578
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Sphingosine-1-phosphate (S1P) is a cellular signalling molecule derived from sphingosine, which is a pro-apoptotic sphingolipid. Sphingolipids control various cellular actions like growth, homeostasis, and stress-related responses. The main sources of S1P in our body are erythrocytes. S1P controls both cellular mediators and other second messengers intracellularly. The S1P receptor also helps in inflammatory and neuroprotective effects (required to manage of Parkinson's). A large number of anti-Parkinson drugs are available, but still, there is a need for more effective and safer drugs. S1P and its receptors could be targeted as novel drugs due to their involvement in neuro-inflammation and Parkinson's. The present review effort to explore the biological role of S1P and related receptors, for their possible involvement in PD; furthermore. Overall, S1P and other related metabolizing enzymes have significant therapeutic opportunities for Parkinson's disease along with other neurological disorders.
引用
收藏
页码：365 / 378
页数：14
相关论文
共 50 条
  • [21] Ceramide and Sphingosine-1-Phosphate in Cell Death Pathways: Relevance to the Pathogenesis of Alzheimer's Disease
    Chakrabarti, Sankha Shubhra
    Bir, Aritri
    Poddar, Jit
    Sinha, Maitrayee
    Ganguly, Anirban
    Chakrabarti, Sasanka
    CURRENT ALZHEIMER RESEARCH, 2016, 13 (11) : 1232 - 1248
  • [22] Hypoxia Conditioning as a Promising Therapeutic Target in Parkinson's Disease?
    Burtscher, Johannes
    Syed, Muhammed Muazzam Kamil
    Lashuel, Hilal A.
    Millet, Gregoire P.
    MOVEMENT DISORDERS, 2021, 36 (04) : 857 - 861
  • [23] Th17 cells: a promising therapeutic target for Parkinson's disease?
    Prots, Iryna
    Winner, Beate
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2019, 23 (04) : 309 - 314
  • [24] Neuromelanin: Its role in the pathogenesis of idiopathic Parkinson's disease and potential as a therapeutic target
    Mitra, Ritoban
    Premraj, Lavienraj
    Khoo, Tien K.
    PARKINSONISM & RELATED DISORDERS, 2023, 112
  • [25] Effects of Sex, Age, and Apolipoprotein E Genotype on Brain Ceramides and Sphingosine-1-Phosphate in Alzheimer's Disease and Control Mice
    den Hoedt, Sandra
    Crivelli, Simone M.
    Leijten, Frank P. J.
    Losen, Mario
    Stevens, Jo A. A.
    Mane-Damas, Marina
    de Vries, Helga E.
    Walter, Jochen
    Mirzaian, Mina
    Sijbrands, Eric J. G.
    Aerts, Johannes M. F. G.
    Verhoeven, Adrie J. M.
    Martinez-Martinez, Pilar
    Mulder, Monique T.
    FRONTIERS IN AGING NEUROSCIENCE, 2021, 13
  • [26] Sex-dependent efficacy of sphingosine-1-phosphate receptor agonist FTY720 in mitigating Huntington's disease
    Wu, Jingyun
    Santos-Garcia, Irene
    Eiriz, Ivan
    Bruning, Thomas
    Kvasnicka, Ales
    Friedecky, David
    Nyman, Tuula A.
    Pahnke, Jens
    PHARMACOLOGICAL RESEARCH, 2025, 211
  • [27] Target oxidative stress-induced disulfidptosis: novel therapeutic avenues in Parkinson's disease
    Zhang, Junshi
    Liu, Tingting
    Wu, Haojie
    Wei, Jianshe
    Qu, Qiumin
    MOLECULAR BRAIN, 2025, 18 (01)
  • [28] Pharmacophore-Based Design of Novel Oxadiazoles as Selective Sphingosine-1-phosphate (S1P) Receptor Agonists with in vivo Efficacy
    Quattropani, Anna
    Sauer, Wolfgang H. B.
    Crosignani, Stefano
    Dorbais, Jerome
    Gerber, Patrick
    Gonzalez, Jerome
    Marin, Delphine
    Muzerelle, Mathilde
    Beltran, Fanny
    Nichols, Anthony
    Georgi, Katrin
    Schneider, Manfred
    Vitte, Pierre-Alain
    Eligert, Valerie
    Novo-Perez, Laurence
    Hantson, Jennifer
    Nock, Sebastien
    Carboni, Susanna
    de Souza, Adriano Luis Soares
    Arrighi, Jean-Francois
    Boschert, Ursula
    Bombrun, Agnes
    CHEMMEDCHEM, 2015, 10 (04) : 688 - 714
  • [29] The gut microbiota: A novel therapeutic target in Parkinson's disease?
    Lubomski, Michal
    Davis, Ryan L.
    Sue, Carolyn M.
    PARKINSONISM & RELATED DISORDERS, 2019, 66 : 265 - 266
  • [30] PARK7/DJ-1 in microglia: implications in Parkinson's disease and relevance as a therapeutic target
    Lind-Holm Mogensen, Frida
    Scafidi, Andrea
    Poli, Aurelie
    Michelucci, Alessandro
    JOURNAL OF NEUROINFLAMMATION, 2023, 20 (01)
12345